{"id":"subcutaneous-enoxaparin-sodium","safety":{"commonSideEffects":[{"rate":"1-10%","effect":"Bleeding"},{"rate":"0.1-1%","effect":"Thrombocytopenia"},{"rate":"5-10%","effect":"Injection site hematoma"},{"rate":"1-5%","effect":"Elevated transaminases"},{"rate":null,"effect":"Osteoporosis (with long-term use)"}]},"_chembl":{"chemblId":"CHEMBL1201476","moleculeType":"Oligosaccharide"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Enoxaparin is derived from unfractionated heparin and works by potentiating antithrombin III, a natural anticoagulant. This leads to inactivation of coagulation factors Xa and IIa (thrombin), preventing thrombus formation. The subcutaneous formulation provides predictable pharmacokinetics and is used for both prophylaxis and treatment of thromboembolism.","oneSentence":"Enoxaparin sodium is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factors Xa and IIa.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:53:40.702Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prophylaxis of venous thromboembolism"},{"name":"Treatment of acute deep vein thrombosis"},{"name":"Treatment of acute pulmonary embolism"},{"name":"Acute coronary syndrome"}]},"trialDetails":[{"nctId":"NCT06454630","phase":"PHASE2","title":"A Trial to Learn How Well REGN7508 Works for Preventing Blood Clots After a Knee Replacement in Adult Participants","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-06-27","conditions":"Venous Thromboembolism","enrollment":179},{"nctId":"NCT07312851","phase":"PHASE1","title":"A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2026-01-19","conditions":"Healthy Participants","enrollment":186},{"nctId":"NCT07384598","phase":"NA","title":"Pharmacokinetic Profiles of Subcutaneous Enoxaparin for Thromboprophylaxis in Critically Ill Patients With Renal Failure Treated or Not With Continuous Veno-veinous Hemofiltration.","status":"NOT_YET_RECRUITING","sponsor":"Clinique Saint Pierre Ottignies","startDate":"2026-02-01","conditions":"Thromboprophylaxis, Critical Illness, Intensive Care (ICU)","enrollment":60},{"nctId":"NCT04273607","phase":"PHASE2, PHASE3","title":"Anticoagulation-free VV ECMO for Acute Respiratory Failure","status":"RECRUITING","sponsor":"Damian Ratano","startDate":"2022-09-01","conditions":"Extracorporeal Membrane Oxygenation Complication","enrollment":40},{"nctId":"NCT07140523","phase":"PHASE2","title":"A Study to Compare the Efficacy and Safety of SRSD107 and Enoxaparin in Adult Subjects Undergoing TKA","status":"RECRUITING","sponsor":"Sirius Therapeutics Co., Ltd.","startDate":"2025-09-16","conditions":"Venous Thromboembolism","enrollment":450},{"nctId":"NCT07330661","phase":"NA","title":"Nursing-Led Deep Vein Thrombosis Prevention in Neurosurgery","status":"COMPLETED","sponsor":"West China Hospital","startDate":"2021-01-01","conditions":"Deep Vein Thrombosis (DVT)","enrollment":1286},{"nctId":"NCT06370273","phase":"PHASE3","title":"Thromboprophylaxis in Lower Limb Immobilisation","status":"RECRUITING","sponsor":"Queen Mary University of London","startDate":"2024-11-12","conditions":"Thrombosis, Injury Leg","enrollment":10044},{"nctId":"NCT07270263","phase":"NA","title":"Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies","status":"RECRUITING","sponsor":"Medical University of Gdansk","startDate":"2024-11-22","conditions":"Lymphoma, Leukemia, Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma","enrollment":100},{"nctId":"NCT07228663","phase":"PHASE3","title":"Hip Fracture Surgery Arterial and Venous Thrombotic Events Prevention","status":"NOT_YET_RECRUITING","sponsor":"McMaster University","startDate":"2025-12-01","conditions":"Hip Fracture Surgery, Cardiovascular Prevention, Venous Thromboembolism (VTE)","enrollment":100},{"nctId":"NCT07213713","phase":"","title":"Evaluation of Anti-Xa Activity in Patients With Severe Obesity After Subcutaneous Injection of Enoxaparin for Antithrombotic Prophylaxis at Two Different Sites.","status":"NOT_YET_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2025-10-01","conditions":"Venous Thromboembolism, Obese Patients","enrollment":80},{"nctId":"NCT07189897","phase":"PHASE4","title":"Apixaban or Enoxaparin After Head and Neck Cancer Surgery","status":"RECRUITING","sponsor":"Kiranya Arnold","startDate":"2025-10","conditions":"Venous Thromboembolism, Head and Neck Cancer","enrollment":76},{"nctId":"NCT03244020","phase":"PHASE4","title":"LMWH vs Aspirin for VTE Prophylaxis in Orthopaedic Oncology","status":"ENROLLING_BY_INVITATION","sponsor":"Massachusetts General Hospital","startDate":"2018-02-16","conditions":"Sarcoma, Soft Tissue Sarcoma, Bone Sarcoma","enrollment":2868},{"nctId":"NCT06180889","phase":"PHASE2","title":"Factor XI inhibiTion for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty","status":"ACTIVE_NOT_RECRUITING","sponsor":"Suzhou Alphamab Co., Ltd.","startDate":"2023-12-20","conditions":"Knee Arthroplasty, Total","enrollment":241},{"nctId":"NCT05618808","phase":"PHASE2","title":"A Trial to Learn How Well REGN9933 Works for Preventing Blood Clots After Knee Replacement Surgery in Adult Participants","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-05-24","conditions":"Venous Thromboembolism","enrollment":373},{"nctId":"NCT04762992","phase":"PHASE3","title":"LMWH for Treatment of Early Fetal Growth Restriction (HepaGrowth)","status":"ENROLLING_BY_INVITATION","sponsor":"Centro Hospitalar de Lisboa Central","startDate":"2022-07-18","conditions":"Fetal Growth Retardation, Prematurity, Pre-Eclampsia","enrollment":12},{"nctId":"NCT06689241","phase":"NA","title":"Rivaroxaban Versus Enoxaparin for Prophylaxis of Venous Thromboembolism in Bariatric Surgery","status":"RECRUITING","sponsor":"Alexandria University","startDate":"2024-10-01","conditions":"Morbid Obesity, Bariatric Surgery Candidate","enrollment":162},{"nctId":"NCT03891524","phase":"PHASE2","title":"A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-06-17","conditions":"Arthroplasty, Replacement, Knee","enrollment":1242},{"nctId":"NCT06795698","phase":"PHASE2","title":"The Effect of Prophylactic Anticoagulation on Major Bleeding Events in Hospitalized Chronic Kidney Disease and Lower Limb Fracture Patients.","status":"COMPLETED","sponsor":"Hospital Civil de Guadalajara","startDate":"2019-03-01","conditions":"Fractures, Bone, CKD Stage 4, CKD Stage 3","enrollment":61},{"nctId":"NCT03532139","phase":"PHASE2","title":"Pilot Study of Rosuvastatin and Enoxaparin Thromboprophylaxis Following Ovarian Cancer Surgery (O-STAT Study)","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2018-07-25","conditions":"Ovarian Cancer","enrollment":24},{"nctId":"NCT05752461","phase":"PHASE2","title":"SHR-2004 for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty","status":"COMPLETED","sponsor":"Beijing Suncadia Pharmaceuticals Co., Ltd","startDate":"2023-04-12","conditions":"Prevention of Venous Thromboembolism After Knee Arthroplasty","enrollment":353},{"nctId":"NCT04710732","phase":"PHASE4","title":"Individual Dose Adjustment of Low-molecular-weight-heparin by Thromodynamics Test.","status":"TERMINATED","sponsor":"Pirogov Russian National Research Medical University","startDate":"2021-03-01","conditions":"Venous Thromboembolism","enrollment":9},{"nctId":"NCT04367831","phase":"PHASE4","title":"Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19","status":"COMPLETED","sponsor":"Columbia University","startDate":"2020-05-02","conditions":"COVID-19, Venous Thromboses, Arterial Thrombosis","enrollment":94},{"nctId":"NCT04427098","phase":"PHASE2","title":"Enoxaparin in COVID-19 Moderate to Severe Hospitalized Patients","status":"COMPLETED","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2020-05-22","conditions":"COVID-19","enrollment":301},{"nctId":"NCT05129800","phase":"","title":"Efficacy of Platelet-Rich Plasma Versus Mesotherapy in Androgenetic Alopecia: A Retrospective Study","status":"COMPLETED","sponsor":"Faculty Hospital Kralovske Vinohrady","startDate":"2011-01-01","conditions":"Androgenetic Alopecia, Hair Loss, Alopecia","enrollment":72},{"nctId":"NCT01717573","phase":"NA","title":"Deferred Stent Trial in STEMI","status":"COMPLETED","sponsor":"NHS National Waiting Times Centre Board","startDate":"2012-03","conditions":"ST-Elevation Myocardial Infarction","enrollment":101},{"nctId":"NCT06442267","phase":"PHASE4","title":"Comparing Anticoagulation Strategies Using UFH, Argatroban and LMWH for ECMO Support","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2024-07-30","conditions":"Respiratory Insufficiency, Circulatory Failure, Thromboembolism","enrollment":90},{"nctId":"NCT06662240","phase":"NA","title":"Effect of Vibration Anesthesia on Pain, Ecchymosis and Comfort Level in Subcutaneous Heparin Injection","status":"COMPLETED","sponsor":"Ataturk University","startDate":"2024-03-15","conditions":"Pain, Ecchymosis, Comfort","enrollment":142},{"nctId":"NCT06531525","phase":"PHASE2","title":"Effect of Low Molecular Heparin on Pregnancy Outcome With Protein S Deficiency","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2024-08-01","conditions":"Pregnancy Related, Protein S Deficiency","enrollment":48},{"nctId":"NCT04508855","phase":"","title":"Management of Atrial Fibrillation in Patients With Cancer (MAFIC Study)","status":"WITHDRAWN","sponsor":"AHEPA University Hospital","startDate":"2020-08-01","conditions":"Cancer, Atrial Fibrillation","enrollment":""},{"nctId":"NCT04164693","phase":"NA","title":"Efficacy and Safety of Short-term Postoperative Anticoagulant Therapy to Prevente Thrombosis in Arterovenous Fistula","status":"COMPLETED","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2019-01-01","conditions":"Thrombosis","enrollment":287},{"nctId":"NCT06416566","phase":"NA","title":"Low-Dose Enoxaparin in Psoriasis","status":"NOT_YET_RECRUITING","sponsor":"Zagazig University","startDate":"2024-05-15","conditions":"Psoriasis","enrollment":30},{"nctId":"NCT02984384","phase":"PHASE3","title":"PREVENTion of Clot in Orthopaedic Trauma","status":"COMPLETED","sponsor":"Major Extremity Trauma Research Consortium","startDate":"2017-04-24","conditions":"Blood Clot, Trauma","enrollment":12424},{"nctId":"NCT06222216","phase":"NA","title":"The Effect of Chilled Needle on the Development of Pain and Ecchymosis in Subcutaneous Injection in Adults","status":"RECRUITING","sponsor":"TC Erciyes University","startDate":"2024-03-01","conditions":"Pain, Ecchymosis, A Randomized Controlled Trial","enrollment":60},{"nctId":"NCT06153394","phase":"PHASE3","title":"Prolonged Hypercoagulability Following Major Liver Resection for Malignancy","status":"NOT_YET_RECRUITING","sponsor":"Western University, Canada","startDate":"2024-06-01","conditions":"Hepatic Disease, Surgery-Complications, Hypercoagulability","enrollment":50},{"nctId":"NCT06293287","phase":"PHASE2","title":"Enoxaparin for Preventing the Radical Artery Occlusion After the Transradial Access Hepatic Arterial Infusion Chemotherapy","status":"UNKNOWN","sponsor":"Zhongshan Hospital (Xiamen), Fudan University","startDate":"2024-01-31","conditions":"Radial Artery Occlusion","enrollment":156},{"nctId":"NCT04409834","phase":"PHASE4","title":"Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial","status":"COMPLETED","sponsor":"The TIMI Study Group","startDate":"2020-08-05","conditions":"COVID-19, Venous Thromboembolism, Arterial Thrombosis","enrollment":390},{"nctId":"NCT04918524","phase":"","title":"The Clinical Features and Pregnancy Outcomes of CTD Patients","status":"RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2018-09-11","conditions":"Connective Tissue Diseases, Pregnancy Related","enrollment":126},{"nctId":"NCT04976465","phase":"PHASE1","title":"Treatment and Clinical Outcomes Among SLE Patients in Pregnancy","status":"RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2018-01-01","conditions":"Systemic Lupus Erythematosus, Pregnancy Related","enrollment":200},{"nctId":"NCT06049758","phase":"NA","title":"D2 Versus D3 Dissection in Laparoscopic Right Hemicolectomy","status":"NOT_YET_RECRUITING","sponsor":"General Committee of Teaching Hospitals and Institutes, Egypt","startDate":"2024-01-02","conditions":"Blood Loss, Intensive Care, Anastomotic Leakage","enrollment":80},{"nctId":"NCT04536363","phase":"PHASE2","title":"Cri Analog PG1 Effectiveness and Safety in Covid-19","status":"WITHDRAWN","sponsor":"Alonso Vera Torres","startDate":"2020-12-03","conditions":"Covid19","enrollment":""},{"nctId":"NCT01583218","phase":"PHASE3","title":"Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)","status":"COMPLETED","sponsor":"Portola Pharmaceuticals","startDate":"2012-03","conditions":"Venous Thromboembolism (VTE)","enrollment":7513},{"nctId":"NCT04646655","phase":"PHASE3","title":"Enoxaparin at Prophylactic or Therapeutic Doses in COVID-19","status":"COMPLETED","sponsor":"ASST Fatebenefratelli Sacco","startDate":"2020-07-27","conditions":"Covid19, Thrombosis","enrollment":142},{"nctId":"NCT02474212","phase":"PHASE4","title":": Pharmacokinetics of Enoxaparin After Coronary Artery Bypass Graft Surgery","status":"COMPLETED","sponsor":"Tampere University Hospital","startDate":"2016-05","conditions":"Venous Thromboembolism, Pulmonary Embolism, Thromboprophylaxis","enrollment":85},{"nctId":"NCT02923115","phase":"PHASE1, PHASE2","title":"Study to Assess the Safety, Pharmacokinetics/Dynamics of DS-1040b in Subjects With Acute Submassive Pulmonary Embolism","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2016-06-23","conditions":"Pulmonary Embolism, Thrombotic Disease","enrollment":134},{"nctId":"NCT01692158","phase":"PHASE1","title":"Pharmacodynamics Study of Enoxalow Compared to Clexane in Healthy Subjects After Subcutaneous Single Dose","status":"COMPLETED","sponsor":"Azidus Brasil","startDate":"2013-03","conditions":"Healthy","enrollment":36},{"nctId":"NCT04492254","phase":"PHASE3","title":"Early Prophylactic Low-molecular-weight Heparin (LMWH) in Symptomatic COVID-19 Positive Patients","status":"TERMINATED","sponsor":"Thrombosis Research Institute","startDate":"2020-10-27","conditions":"COVID-19","enrollment":219},{"nctId":"NCT04600141","phase":"PHASE3","title":"Clinical Efficacy of Heparin and Tocilizumab in Patients With Severe COVID-19 Infection","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2020-11-10","conditions":"Covid19","enrollment":308},{"nctId":"NCT05265676","phase":"PHASE1","title":"Bioequivalence Study of a Generic Enoxaparin Sodium to Clexane® After Single Subcutaneous Dose in Healthy Human Subjects","status":"COMPLETED","sponsor":"Venus Remedies Limited","startDate":"2021-02-26","conditions":"Healthy","enrollment":24},{"nctId":"NCT02774265","phase":"PHASE3","title":"A Different Approach to Preventing Thrombosis","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2016-01","conditions":"Venous Thromboembolism, Pulmonary Embolism","enrollment":329},{"nctId":"NCT05172115","phase":"PHASE3","title":"Catheter-Directed Thrombolysis Versus Anticoagulation Monotherapy in Intermediate-High Risk PE","status":"TERMINATED","sponsor":"Rajaie Cardiovascular Medical and Research Center","startDate":"2018-12-22","conditions":"Pulmonary Embolism, Pulmonary Thromboembolisms, Embolism, Pulmonary","enrollment":94},{"nctId":"NCT04401293","phase":"PHASE3","title":"Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients","status":"COMPLETED","sponsor":"Northwell Health","startDate":"2020-04-26","conditions":"Sars-CoV2, COVID","enrollment":257},{"nctId":"NCT04345848","phase":"PHASE3","title":"Preventing COVID-19 Complications With Low- and High-dose Anticoagulation","status":"TERMINATED","sponsor":"University Hospital, Geneva","startDate":"2020-04-28","conditions":"COVID, Sars-CoV2","enrollment":160},{"nctId":"NCT01573169","phase":"PHASE3","title":"PREvention of VENous Thromboembolism In Hemorrhagic Stroke Patients","status":"TERMINATED","sponsor":"University Of Perugia","startDate":"2012-05","conditions":"Hemorrhagic Stroke, Venous Thromboembolism, Deep Venous Thrombosis","enrollment":73},{"nctId":"NCT04999176","phase":"PHASE3","title":"Venous Thromboembolism Prophylaxis After Gynecological Pelvic Cancer Surgery With Rivaroxaban vs Enoxaparin","status":"UNKNOWN","sponsor":"André Luiz Malavasi Longo de Oliveira","startDate":"2020-10-22","conditions":"Cancer, Rivaroxaban, Venous Thromboembolism","enrollment":440},{"nctId":"NCT04372589","phase":"PHASE2, PHASE3","title":"Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC)","status":"COMPLETED","sponsor":"University of Manitoba","startDate":"2020-05-20","conditions":"COVID-19, Pneumonia","enrollment":1200},{"nctId":"NCT04640181","phase":"PHASE2","title":"Factor Xa Inhibitor Versus Standard of Care Heparin in Hospitalized Patients With COVID-19 (XACT)","status":"COMPLETED","sponsor":"St. David's HealthCare","startDate":"2020-12-01","conditions":"Covid19","enrollment":150},{"nctId":"NCT04366960","phase":"PHASE3","title":"Comparison of Two Doses of Enoxaparin for Thromboprophylaxis in Hospitalized COVID-19 Patients","status":"COMPLETED","sponsor":"Niguarda Hospital","startDate":"2020-05-14","conditions":"Covid19","enrollment":189},{"nctId":"NCT04584580","phase":"PHASE4","title":"D-dimer Adjusted Versus Therapeutic Dose Low-molecular-weight Heparin in Patients With COVID-19 Pneumonia","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2020-08-01","conditions":"Coronavirus Disease (COVID)19","enrollment":50},{"nctId":"NCT00633061","phase":"PHASE2","title":"Identification and Treatment of Clinically Silent Catheter-Related Deep Vein Thrombosis in Children With Cancer","status":"TERMINATED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2008-06","conditions":"Childhood Cancer, Central Venous Catheters, Deep Vein Thrombosis","enrollment":136},{"nctId":"NCT03393481","phase":"PHASE2","title":"Prevention of Thromboembolic Events in Total Knee Replacement Patients","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2018-10-03","conditions":"Thrombotic Disorders","enrollment":""},{"nctId":"NCT04530578","phase":"PHASE4","title":"Nebulized Heparin in Severe Acute Respiratory Syndrome COVID-19","status":"UNKNOWN","sponsor":"Clinica San Camilo, Argentina","startDate":"2020-06-01","conditions":"Covid19, Pneumonia","enrollment":200},{"nctId":"NCT01763606","phase":"NA","title":"Enoxaparin Versus Aspirin in Patients With Cancer and Stroke","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2012-12-18","conditions":"Cancer Patients First-ever Acute Ischemic Stroke","enrollment":20},{"nctId":"NCT03528967","phase":"PHASE4","title":"Enoxaparin in the Prevention of Placental Insufficiency in Pregnant Women","status":"COMPLETED","sponsor":"Les Laboratoires des Médicaments Stériles","startDate":"2013-10-23","conditions":"Placental Insufficiency, Enoxaparin","enrollment":89},{"nctId":"NCT02206100","phase":"PHASE1, PHASE2","title":"PK and PD of Single, Escalating Doses of PER977 Following Enoxaparin","status":"COMPLETED","sponsor":"Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.","startDate":"2014-04","conditions":"Healthy","enrollment":40},{"nctId":"NCT04344756","phase":"PHASE2","title":"Trial Evaluating Efficacy and Safety of Anticoagulation in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-04-20","conditions":"COVID19 Pneumonia","enrollment":808},{"nctId":"NCT02366871","phase":"PHASE2","title":"Oral Apixaban (Eliquis) Versus Enoxaparin (Lovenox) for Thromboprophylaxis in Women With Suspected Pelvic Malignancy","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2015-04-28","conditions":"Gynecologic Cancer, Venous Thromboembolism","enrollment":400},{"nctId":"NCT03276143","phase":"PHASE2","title":"FactOr XIa inhibiTion for the pRevention of venOus Thromboembolism in Patients Undergoing Total Knee Arthroplasty","status":"COMPLETED","sponsor":"Bayer","startDate":"2017-09-21","conditions":"Knee Arthroplasty, Total","enrollment":813},{"nctId":"NCT03200613","phase":"PHASE2","title":"Apixaban For Thromboprophylaxis In Patients With Acute Spinal Cord Injury","status":"TERMINATED","sponsor":"McMaster University","startDate":"2017-09-01","conditions":"Spinal Cord Injuries, Venous Thromboembolism","enrollment":8},{"nctId":"NCT04169269","phase":"PHASE4","title":"Deep Vein Thrombosis Prophylaxis Adherence: Enoxaparin vs Rivaroxaban","status":"UNKNOWN","sponsor":"Florida Orthopaedic Institute","startDate":"2020-01-13","conditions":"Deep Vein Thrombosis, Venous Thromboembolism","enrollment":128},{"nctId":"NCT02396732","phase":"PHASE4","title":"Aspirin and Enoxaparin for VTE in Trauma","status":"TERMINATED","sponsor":"University of Miami","startDate":"2016-02","conditions":"Venous Thromboembolism, Thromboprophylaxis, Trauma","enrollment":31},{"nctId":"NCT03671174","phase":"NA","title":"Immunosuppressant Regimens for Living Fetuses Study","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2019-08-02","conditions":"Undifferentiated Connective Tissue Disease, Recurrent Pregnancy Loss","enrollment":420},{"nctId":"NCT03962075","phase":"NA","title":"Short-term Outcomes of Laparoscopic Repair of Paravaginal Defects","status":"COMPLETED","sponsor":"Zagazig University","startDate":"2016-08-01","conditions":"Prolapse, Vaginal, Paravaginal Cystocele","enrollment":50},{"nctId":"NCT01181102","phase":"PHASE3","title":"A Phase 3 Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2009-03","conditions":"Venous Thromboembolism","enrollment":716},{"nctId":"NCT01181141","phase":"PHASE3","title":"Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Hip Fracture Surgery","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2008-10","conditions":"Venous Thromboembolism","enrollment":92},{"nctId":"NCT01181167","phase":"PHASE3","title":"A Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2009-05","conditions":"Prevention, Venous Thromboembolism","enrollment":610},{"nctId":"NCT01662908","phase":"PHASE2","title":"A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2012-08","conditions":"Deep Vein Thrombosis, Venous Thrombosis","enrollment":85},{"nctId":"NCT01203098","phase":"PHASE2","title":"A Phase 2b Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2008-07","conditions":"Venous Thromboembolism, Thromboembolism, Thrombosis","enrollment":264},{"nctId":"NCT03841396","phase":"PHASE4","title":"A Study Comparing the Local Tolerability of Two Subcutaneous Heparins in Healthy Volunteers.","status":"COMPLETED","sponsor":"Aspen Global Incorporated","startDate":"2016-06-02","conditions":"Injection Site Reaction","enrollment":15},{"nctId":"NCT03814278","phase":"NA","title":"Bed Rest After Preterm Premature Rupture of the Membranes","status":"COMPLETED","sponsor":"Centro Hospitalar Lisboa Norte","startDate":"2012-01","conditions":"Preterm Premature Rupture of Membrane","enrollment":32},{"nctId":"NCT00413374","phase":"NA","title":"Once Daily Enoxaparin for Outpatient Treatment of Acute DVT and/or Pulmonary Embolism","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2006-05","conditions":"Deep Vein Thrombosis, Pulmonary Embolism","enrollment":40},{"nctId":"NCT03570281","phase":"PHASE2, PHASE3","title":"Edoxaban for the Treatment of Coagulopathy in Patients With Active Cancer and Acute Ischemic Stroke: a Pilot Study. (ENCHASE Study)","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2018-06-15","conditions":"Correction of Cancer-related Coagulopathy With Novel Oral Anticoagulant (Edoxaban)","enrollment":40},{"nctId":"NCT01965002","phase":"NA","title":"Feasibility of ExAblate MRI Guided High Intensity Focused Ultrasound Tx of Soft Tissue Tumors","status":"TERMINATED","sponsor":"Pejman Ghanouni","startDate":"2014-05","conditions":"Soft Tissue Neoplasms","enrollment":5},{"nctId":"NCT00585182","phase":"PHASE4","title":"Study to Evaluate Weight-based Enoxaparin Dosing in Obese Medical Patients at Risk for DVT","status":"COMPLETED","sponsor":"University of Utah","startDate":"2007-01","conditions":"Obesity, Venous Thrombosis, Anticoagulants","enrollment":28},{"nctId":"NCT02271295","phase":"PHASE3","title":"Impact on Morbidity and Mortality of Prophylactic Dosing of Low Molecular Heparin in Child-Pugh B Cirrhotic Patients","status":"SUSPENDED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-07-27","conditions":"Cirrhosis","enrollment":16},{"nctId":"NCT03363477","phase":"PHASE1","title":"Study of Pharmacodynamic Equivalence of Enoxaparin Rovi to Clexane®, in Healthy Volunteers","status":"COMPLETED","sponsor":"Rovi Pharmaceuticals Laboratories","startDate":"2015-09-25","conditions":"Healthy","enrollment":46},{"nctId":"NCT02095509","phase":"PHASE4","title":"Pharmacokinetics of Enoxaparin in Intensive Care Patients","status":"COMPLETED","sponsor":"Tampere University Hospital","startDate":"2014-03","conditions":"Venous Thromboembolism","enrollment":39},{"nctId":"NCT00717938","phase":"PHASE3","title":"A Study of Standard Treatment +/- Enoxaparin in Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Lund University Hospital","startDate":"2008-06","conditions":"Small Cell Lung Cancer","enrollment":390},{"nctId":"NCT03254511","phase":"PHASE2","title":"Addition of Enoxaparin to Neoadjuvant Chemoradiation of Esophageal Cancer","status":"UNKNOWN","sponsor":"Mashhad University of Medical Sciences","startDate":"2016-07-22","conditions":"Esophageal Neoplasms","enrollment":100},{"nctId":"NCT00774748","phase":"NA","title":"Once Weekly Subcutaneous Ports for the Administration of Anticoagulants","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2008-08","conditions":"Venous Thromboembolism","enrollment":21},{"nctId":"NCT03088358","phase":"PHASE2","title":"Safety and Efficacy of TeaRx Xa Factor Direct Inhibitor Versus Enoxaparin as a Venous Thromboembolic Events (VTE) Prevention Following Total Knee Replacement","status":"COMPLETED","sponsor":"TeaRx LLC","startDate":"2013-08","conditions":"Total Knee Replacement","enrollment":200},{"nctId":"NCT01608347","phase":"PHASE4","title":"Low Molecular Weight Heparin in Recurrent Miscarriage With Negative Antiphospholipid Antibodies","status":"COMPLETED","sponsor":"Omar Mamdouh Shaaban","startDate":"2010-01","conditions":"Recurrent Miscarriage","enrollment":228},{"nctId":"NCT01388322","phase":"PHASE3","title":"Low Weight Heparin prOphylaxis for Placental-Mediated Complications of PrEgnancy","status":"COMPLETED","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","startDate":"2012-03","conditions":"High Risk Pregnant Women, Placental Insufficiency, Preeclampsia","enrollment":361},{"nctId":"NCT00571649","phase":"PHASE3","title":"Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-12","conditions":"Venous Thromboembolism","enrollment":8101},{"nctId":"NCT02795065","phase":"NA","title":"Bemiparin Versus Enoxaparin in the Prevention of Venous Thromboembolism Among ICU Patients","status":"COMPLETED","sponsor":"Mohamed Sayed Mohamed Abbas","startDate":"2014-03","conditions":"Venous Thromboembolism","enrollment":100},{"nctId":"NCT00351663","phase":"PHASE4","title":"The Effect of Vasopressors on the Anti Xa Response to Enoxaparin in Critically Ill Patients","status":"COMPLETED","sponsor":"Shaare Zedek Medical Center","startDate":"2007-02","conditions":"Venous Thrombosis, Critical Illness","enrollment":39},{"nctId":"NCT00641732","phase":"PHASE2","title":"Efficacy and Safety of TAK-442 in Subjects Undergoing Total Knee Replacement","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-10","conditions":"Venous Thromboembolism","enrollment":1045},{"nctId":"NCT00345618","phase":"PHASE3","title":"Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-06","conditions":"Embolism, Thrombosis","enrollment":3202},{"nctId":"NCT02696330","phase":"PHASE4","title":"Comparison Between Effect of Enoxaparin and Clopidogrel on Improving Pregnancy Rate in ICSI","status":"UNKNOWN","sponsor":"Ain Shams Maternity Hospital","startDate":"2015-09","conditions":"Female , Infertility","enrollment":150},{"nctId":"NCT01880216","phase":"PHASE3","title":"Efficacy of Bemiparin Versus Enoxaparin in the Treatment of DVT","status":"COMPLETED","sponsor":"Berlin-Chemie AG Menarini Group","startDate":"2013-06","conditions":"Deep Vein Thrombosis","enrollment":312},{"nctId":"NCT00371683","phase":"PHASE3","title":"Study of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2006-11","conditions":"Deep Vein Thrombosis, Pulmonary Embolism","enrollment":3608}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":22,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lovenox","experimental"],"phase":"phase_3","status":"active","brandName":"Subcutaneous enoxaparin sodium","genericName":"Subcutaneous enoxaparin sodium","companyName":"Zhongshan Hospital (Xiamen), Fudan University","companyId":"zhongshan-hospital-xiamen-fudan-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Enoxaparin sodium is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factors Xa and IIa. Used for Prophylaxis of venous thromboembolism, Treatment of acute deep vein thrombosis, Treatment of acute pulmonary embolism.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}